ABSK141 / Abbisko - LARVOL DELTA

Heyu Pharmaceuticals' Potential Best-In-Class PRMT5*MTA Inhibitor Debuts at the 36th ENA Conference [Google translation] (bydrug.pharmcube.com) - "On October 23, Heyu Pharmaceuticals issued an announcement stating that the company's two preclinical research results were released at the 36th International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR conference...ABSK131 presented by Heyu Pharmaceuticals is a highly selective brain-accessible MTA-synergistic PRMT5 inhibitor, and its excellent properties support its rapid preclinical development...In in vitro experiments, ABSK141 showed high binding ability and good biochemical activity for KRASG12D. It also showed strong inhibitory effects on KRAS downstream signaling pathways and efficient anti-proliferation ability in a series of KRASG12D tumor cell lines. In vivo efficacy experiments also showed the strong anti-tumor ability of ABSK141 in multiple different KRASG12D tumor models."

Preclinical • Oncology

Discovery and characterization of a high orally available small molecule inhibitor of KRASG12D (EORTC-NCI-AACR 2024) - "Preclinical DMPK analysis demonstrated excellent bioavailability across several animal species. Together, the superior preclinical profile of ABSK141 support its fast-track preclinical development."

Colorectal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • KRAS